- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04471844
Studio cardine, randomizzato, in aperto di Optune® (campi di trattamento del tumore) in concomitanza con RT e TMZ per il trattamento del GBM di nuova diagnosi (EF-32)
EF-32: studio cardine, randomizzato, in aperto su Optune® (campi di trattamento del tumore, 200kHz) in concomitanza con radioterapia e temozolomide per il trattamento del glioblastoma di nuova diagnosi
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
Panoramica dello studio
Descrizione dettagliata
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Innsbruck
-
Innsbruck, Innsbruck, Austria, 6020
- Innsbruck University Hospital
-
-
Linz
-
Linz, Linz, Austria, 4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Austria, 5020
- University Hospital Salzburg
-
-
-
-
-
Liège, Belgio, B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa, Ontario, Canada
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Canada
- Princess Margaret Cancer Centre
-
Toronto, Ontario, Canada
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke, Quebec, Canada
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
Brno
-
Brno, Brno, Cechia, 656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen, Pilsen, Cechia, 305 99
- University Hospital Plzeň
-
-
Prague
-
Prague, Prague, Cechia, 150 30
- Na Homolce Hospital
-
-
-
-
-
Angers, Francia, 49055
- Institut de cancérologie de l'Ouest
-
Bron, Francia, 69677
- Pierre Wertheimer Hospital
-
Marseille, Francia, 13305
- Hôpital la Timone
-
Nice, Francia, 06000
- University Hospital Nice
-
Paris, Francia, 75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain, Francia, 44800
- Institut de cancérologie de l'Ouest
-
Toulouse, Francia, 31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif, Francia, 94805
- Gustave Roussy Institute
-
-
-
-
-
Essen, Germania, 45147
- University Hospital Essen
-
Freiburg im Breisgau, Germania, 79106
- University Medical Center Freiburg
-
Leipzig, Germania, 04103
- University Hospital Leipzig
-
Munich, Germania, 81675
- Rechts der Isar Hospital
-
Tübingen, Germania, 72076
- University Hospital Tübingen
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Giappone, 920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi, Saitama, Giappone, 350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi, Tokyo-To, Giappone, 181-8611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo-To, Giappone, 162-8666
- Tokyo Women's Medical University Hospital
-
-
-
-
-
Jerusalem, Israele, 9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa, Haifa District, Israele, 3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva, Petah Tikva, Israele, 49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan, Ramat Gan, Israele, 52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israele, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Liverpool, Regno Unito, L7 8YA
- Clatterbridge Cancer Centre
-
London, Regno Unito, SE1 9RT
- Guy's Hospital
-
London, Regno Unito, W6 8RF
- Charing Cross Hospital
-
Nottingham, Regno Unito, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston, Regno Unito, PR29HT
- Royal Preston Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Stati Uniti, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, Stati Uniti, 85054
- Mayo Clinic- Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville, Arkansas, Stati Uniti, 72762
- Highlands Oncology Group
-
-
California
-
Burbank, California, Stati Uniti, 91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte, California, Stati Uniti, 91010
- City of Hope National Medical Center
-
Fullerton, California, Stati Uniti, 92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla, California, Stati Uniti, 92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles, California, Stati Uniti, 90048
- Cedars - Sinai Medical Center
-
Los Angeles, California, Stati Uniti, 90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach, California, Stati Uniti, 92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange, California, Stati Uniti, 92868
- St. Joseph Hospital of Orange
-
Orange, California, Stati Uniti, 92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto, California, Stati Uniti, 94303
- Stanford University Cancer Institute
-
San Diego, California, Stati Uniti, 92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco, California, Stati Uniti, 94143
- University of California San Francisco Medical Center
-
Santa Monica, California, Stati Uniti, 90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- University of Colorado Cancer Center Anschutz
-
Englewood, Colorado, Stati Uniti, 80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville, Florida, Stati Uniti, 32224
- Mayo Clinic
-
Jacksonville, Florida, Stati Uniti, 32207
- Baptist Health - Jacksonville
-
Orlando, Florida, Stati Uniti, 32804
- AdventHealth
-
Orlando, Florida, Stati Uniti, 32806
- Orlando Health UF Health Cancer Center
-
Tampa, Florida, Stati Uniti, 33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30342
- Northside Hospital, Inc.
-
Atlanta, Georgia, Stati Uniti, 30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta, Georgia, Stati Uniti, 30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Rush University Medical Center
-
Chicago, Illinois, Stati Uniti, 60617
- University of Chicago
-
-
Indiana
-
Fort Wayne, Indiana, Stati Uniti, 46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka, Kansas, Stati Uniti, 66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, Stati Uniti, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans, Louisiana, Stati Uniti, 70072
- LSU Health Sciences Center, New Orleans
-
New Orleans, Louisiana, Stati Uniti, 70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland, Maine, Stati Uniti, 04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Tufts Medical Center
-
Worcester, Massachusetts, Stati Uniti, 01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City, Missouri, Stati Uniti, 64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, Stati Uniti, 08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City, New Jersey, Stati Uniti, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success, New York, Stati Uniti, 11042
- Northwell Health System Brain Tumor Center
-
New York, New York, Stati Uniti, 10029
- Mount Sinai - Icahn School of Medicine
-
New York, New York, Stati Uniti, 10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York, New York, Stati Uniti, 10032
- New York Presbyterian - Columbia University
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester Medical Center
-
Syracuse, New York, Stati Uniti, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Stati Uniti, 28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville, North Carolina, Stati Uniti, 27834
- Vidant Medical Center
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, Stati Uniti, 43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- SCRI - Tennessee Oncology
-
Germantown, Tennessee, Stati Uniti, 38138
- West Cancer Center - Germantown
-
Nashville, Tennessee, Stati Uniti, 37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas, Texas, Stati Uniti, 75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth, Texas, Stati Uniti, 76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston, Texas, Stati Uniti, 77030
- Houston Methodist Hospital
-
Houston, Texas, Stati Uniti, 77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple, Texas, Stati Uniti, 76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98122
- Swedish Health Services
-
Seattle, Washington, Stati Uniti, 98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University Cancer Institute
-
-
-
-
-
Lausanne, Svizzera, CH-1011
- Lausanne University Hospital
-
Zurich, Svizzera, 8091
- University Hospital Zurich
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
Comparatore attivo: RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: 5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression Free Survival (PFS)
Lasso di tempo: 5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
Lasso di tempo: 5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
Lasso di tempo: 5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
Lasso di tempo: 5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
Lasso di tempo: 5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
Lasso di tempo: 5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
Lasso di tempo: 5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
Lasso di tempo: 5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TRIDENT EF-32
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .